UNSPSC 51285404: Cefoxazole

This classification denotes a cephalosporin antibiotic with the molecular formula C21H18ClN3O7S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) BN10X2TL6I, chemically known as 5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 3-((acetoxy)methyl)-7-(((3-(2-chlorophenyl)-5-methyl-4-isoxazolyl)carbonyl)amino)-8-oxo-, (6r-trans)- but more generally known as cefoxazole, which bears US NIH Compound Identifier 65798.

UNSPSC 51285404 Cefoxazole, a Commodity code, shows minimal recent state and local procurement activity directly aligned with the code's pharmaceutical scope. The recent opportunities tagged under this code do not involve cefoxazole procurement; instead, they reflect broader pharmaceutical and medical supply sourcing across multiple product categories, including naloxone, generic multi-source pharmaceuticals, over-the-counter products, and emergency medical supplies. State and local buyers under these broader pharmaceutical and medical-supply codes include county health departments, state health agencies, municipal fire departments, and cooperative purchasing alliances serving multiple jurisdictions. The City of Tampa Fire Department's procurement of emergency medical and first-aid supplies (IFB, response due March 13, 2026, estimated contract value $700,000) and Seminole County's sourcing of naloxone and drug deactivation systems (IFB60459723LAS, response due July 26, 2023) illustrate the kinds of health and emergency-response entities driving volume in this commodity family.

Geographic activity spans Florida, Texas, and Minnesota, with the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) administering a statewide pharmaceutical RFP (S1070000015802, response due March 26, 2026) that includes participating jurisdictions in Oregon. The Texas Health and Human Services Commission's RFI on direct-to-manufacturer prescription programs (HHS0017013, posted April 3, 2026) signals emerging state interest in alternative pharmacy distribution models. However, because the recent opportunities reflect procurement of naloxone, emergency medical supplies, and generic pharmaceuticals rather than cefoxazole specifically, the code appears to suffer from a tagging mismatch — the code name does not align with the work actually being solicited. Firms evaluating this code should verify current demand for cefoxazole specifically through direct outreach to state pharmacy benefit managers and health department procurement offices before committing resources to pursue opportunities tagged here.